Drug Profile

Research programme: 225-Actinium based anticancer therapeutics - SK Biopharmaceuticals/Korea Institute of Radiological and Medical Sciences

Latest Information Update: 07 Feb 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator SK biopharmaceuticals
Developer Korea Institute of Radiological and Medical Sciences; SK biopharmaceuticals
Class Antineoplastics; Radioisotopes; Radiopharmaceuticals
Mechanism of Action Ionising radiation emitters

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

18 Nov 2024 SK Biopharmaceuticals and Korea Institute of Radiological and Medical Sciences agree to co-develop 225-Actinium based anticancer therapeutics in for Cancer
18 Nov 2024 Early research in Cancer in South Korea (Parenteral)
18 Nov 2024 SK Biopharmaceuticals announces intention to submit IND application for Cancer by 2027

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com